Carcinoma, Non-Small-Cell Lung

"Carcinoma, Non-Small-Cell Lung" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.

Descriptor ID	D002289
MeSH Number(s)	C04.588.894.797.520.109.220.249 C08.381.540.140.500 C08.785.520.100.220.500
Concept/Terms	Carcinoma, Non-Small-Cell Lung Carcinoma, Non-Small-Cell Lung Carcinoma, Non Small Cell Lung Carcinomas, Non-Small-Cell Lung Lung Carcinoma, Non-Small-Cell Lung Carcinomas, Non-Small-Cell Non-Small-Cell Lung Carcinomas Nonsmall Cell Lung Cancer Non-Small-Cell Lung Carcinoma Non Small Cell Lung Carcinoma Carcinoma, Non-Small Cell Lung Non-Small Cell Lung Cancer

Below are MeSH descriptors whose meaning is more general than "Carcinoma, Non-Small-Cell Lung".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Thoracic Neoplasms [C04.588.894]
Respiratory Tract Neoplasms [C04.588.894.797]
Lung Neoplasms [C04.588.894.797.520]
Bronchial Neoplasms [C04.588.894.797.520.109]
Carcinoma, Bronchogenic [C04.588.894.797.520.109.220]
Carcinoma, Non-Small-Cell Lung [C04.588.894.797.520.109.220.249]
Respiratory Tract Diseases [C08]
Lung Diseases [C08.381]
Lung Neoplasms [C08.381.540]
Carcinoma, Bronchogenic [C08.381.540.140]
Carcinoma, Non-Small-Cell Lung [C08.381.540.140.500]
Respiratory Tract Neoplasms [C08.785]
Lung Neoplasms [C08.785.520]
Bronchial Neoplasms [C08.785.520.100]
Carcinoma, Bronchogenic [C08.785.520.100.220]
Carcinoma, Non-Small-Cell Lung [C08.785.520.100.220.500]

Below are MeSH descriptors whose meaning is related to "Carcinoma, Non-Small-Cell Lung".

Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Non-Small-Cell Lung".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Carcinoma, Non-Small-Cell Lung" by people in this website by year, and whether "Carcinoma, Non-Small-Cell Lung" was a major or minor topic of these publications.

Bar chart showing 121 publications over 25 distinct years, with a maximum of 10 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
1999	0	1	1
2000	0	1	1
2003	1	0	1
2004	2	1	3
2005	3	0	3
2006	5	0	5
2007	5	1	6
2008	5	0	5
2009	5	1	6
2010	2	2	4
2011	10	0	10
2012	7	1	8
2013	3	1	4
2014	4	3	7
2015	5	0	5
2016	8	0	8
2017	3	1	4
2018	6	1	7
2019	8	0	8
2020	5	0	5
2021	6	0	6
2022	8	0	8
2023	2	0	2
2024	3	0	3

Below are the most recent publications written about "Carcinoma, Non-Small-Cell Lung" by people in Profiles.

Babu S, Horowitz M, Delgado-Coka LA, Roa-Pe?a L, Akalin A, Escobar-Hoyos LF, Shroyer KR. Keratin 17 and A2ML1 are negative prognostic biomarkers in non-small cell lung cancer. Pathol Res Pract. 2024 Nov; 263:155643.

View in: PubMed
Watkins AA, Rizvi TZ, Lopez E, Shehata D, Ssemaganda H, Lin Z, Stock CT, Moffatt-Bruce SD, Servais EL. Trends and comparative outcomes between operative approaches for segmentectomy in lung cancer. J Thorac Cardiovasc Surg. 2025 Mar; 169(3):745-752.e2.

View in: PubMed
McCrury M, Swafford K, Shuttleworth SL, Mehdi SH, Acharya B, Saha D, Naceanceno K, Byrum SD, Storey AJ, Xu YZ, Doshier C, Patel V, Post GR, De Loose A, Rodriguez A, Shultz LD, Zhan F, Yoon D, Frett B, Kendrick S. Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma. Mol Cancer Ther. 2024 Mar 04; 23(3):316-329.

View in: PubMed
Dora D, Ligeti B, Kovacs T, Revisnyei P, Galffy G, Dulka E, Krizs?n D, Kalcsevszki R, Megyesfalvi Z, Dome B, Weiss GJ, Lohinai Z. Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status. Oncoimmunology. 2023; 12(1):2204746.

View in: PubMed
Iyengar P, All S, Berry MF, Boike TP, Bradfield L, Dingemans AC, Feldman J, Gomez DR, Hesketh PJ, Jabbour SK, Jeter M, Josipovic M, Lievens Y, McDonald F, Perez BA, Ricardi U, Ruffini E, De Ruysscher D, Saeed H, Schneider BJ, Senan S, Widder J, Guckenberger M. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline. Pract Radiat Oncol. 2023 Sep-Oct; 13(5):393-412.

View in: PubMed
Santoni M, Rizzo A, Kucharz J, Mollica V, Rosellini M, Marchetti A, Tassinari E, Monteiro FSM, Soares A, Molina-Cerrillo J, Grande E, Battelli N, Massari F. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunol Immunother. 2023 Jun; 72(6):1365-1379.

View in: PubMed
Kneuertz PJ, Abdel-Rasoul M, D'Souza DM, Moffatt-Bruce SD, Merritt RE. Prevalence and Predictability of Occult Satellite Nodules in Clinical Stage Ia Non-small Cell Lung Cancer following Lobectomy. Clin Lung Cancer. 2023 05; 24(3):e134-e140.

View in: PubMed
Suaiti L, Sullivan TB, Rieger-Christ KM, Servais EL, Suzuki K, Burks EJ. Vascular Invasion Predicts Recurrence in Stage IA2-IB Lung Adenocarcinoma but not Squamous Cell Carcinoma. Clin Lung Cancer. 2023 05; 24(3):e126-e133.

View in: PubMed
Kneuertz PJ, Abdel-Rasoul M, D'Souza DM, Moffatt-Bruce SD, Merritt RE. Wedge Resection vs Lobectomy for Clinical Stage IA Non-Small Cell Lung Cancer With Occult Lymph Node Disease. Ann Thorac Surg. 2023 06; 115(6):1344-1351.

View in: PubMed
da Silva-Oliveira RJ, Gomes INF, da Silva LS, Lengert AVH, Laus AC, Melendez ME, Munari CC, Cury FP, Longato GB, Reis RM. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines. Int J Mol Sci. 2022 Jul 14; 23(14).

View in: PubMed

People

Explore

Similar Concepts

Top Journals